Five-Year Trial of Deferiprone Chelation Therapy in Thalassaemia major Patients

Publisher： Karger

E-ISSN： 1421-9662|112|4|179-183

ISSN： 0001-5792

Source： Acta Haematologica, Vol.112, Iss.4, 2004-11, pp. : 179-183

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Deferiprone Chelation Therapy for Thalassemia Major

By  

Acta Haematologica, Vol. 122, Iss. 2-3, 2009-11 ,pp. : 155-164

Karger

Access to resources Recommend Favorite

Renal Dysfunction in Patients with Beta-Thalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with Deferasirox

By  

Acta Haematologica, Vol. 123, Iss. 3, 2010-02 ,pp. : 148-152

Karger

Access to resources Recommend Favorite

Factors Influencing Effectiveness of Deferiprone in a Thalassaemia major Clinical Setting

By  

Acta Haematologica, Vol. 104, Iss. 2-3, 2001-01 ,pp. : 99-102

Karger

Access to resources Recommend Favorite

Effects of Deferiprone on Immune Status and Cytokine Pattern in Thalassaemia major

By  

Acta Haematologica, Vol. 108, Iss. 3, 2002-09 ,pp. : 144-149

Karger

Access to resources Recommend Favorite

Sequential Use of Deferiprone and Desferrioxamine in Primary School Children with Thalassaemia major in Turkey

By  

Acta Haematologica, Vol. 102, Iss. 1, 1999-09 ,pp. : 17-21

Karger

Access to resources Recommend Favorite